NO920127D0 - Fremgangsmaate for behandling eller forhindring av autoimmun uveoretinitis i pattedyr - Google Patents

Fremgangsmaate for behandling eller forhindring av autoimmun uveoretinitis i pattedyr

Info

Publication number
NO920127D0
NO920127D0 NO920127A NO920127A NO920127D0 NO 920127 D0 NO920127 D0 NO 920127D0 NO 920127 A NO920127 A NO 920127A NO 920127 A NO920127 A NO 920127A NO 920127 D0 NO920127 D0 NO 920127D0
Authority
NO
Norway
Prior art keywords
uveoretinitis
mammals
treatment
autoimmun
prevention
Prior art date
Application number
NO920127A
Other languages
English (en)
Norwegian (no)
Other versions
NO920127L (no
Inventor
Howard L Weiner
David A Hafler
Robert B Nussenblatt
Alan G Palestine
Original Assignee
Autoimmune Inc
Brigham & Womens Hospital
Nat Inst Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc, Brigham & Womens Hospital, Nat Inst Health filed Critical Autoimmune Inc
Publication of NO920127L publication Critical patent/NO920127L/no
Publication of NO920127D0 publication Critical patent/NO920127D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Emergency Protection Circuit Devices (AREA)
NO920127A 1989-07-14 1992-01-09 Fremgangsmaate for behandling eller forhindring av autoimmun uveoretinitis i pattedyr NO920127D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37977889A 1989-07-14 1989-07-14
US55163290A 1990-07-10 1990-07-10
PCT/US1990/003989 WO1991001333A1 (en) 1989-07-14 1990-07-16 Methods of treating or preventing autoimmune uveoretinitis in mammals

Publications (2)

Publication Number Publication Date
NO920127L NO920127L (no) 1992-01-09
NO920127D0 true NO920127D0 (no) 1992-01-09

Family

ID=27008768

Family Applications (1)

Application Number Title Priority Date Filing Date
NO920127A NO920127D0 (no) 1989-07-14 1992-01-09 Fremgangsmaate for behandling eller forhindring av autoimmun uveoretinitis i pattedyr

Country Status (15)

Country Link
US (1) US5961977A (ja)
EP (1) EP0482089B1 (ja)
JP (1) JP2607751B2 (ja)
KR (1) KR0159046B1 (ja)
AT (1) ATE158950T1 (ja)
AU (1) AU670024B2 (ja)
BR (1) BR9007527A (ja)
CA (1) CA2063416C (ja)
DE (1) DE69031563T2 (ja)
DK (1) DK0482089T3 (ja)
ES (1) ES2109234T3 (ja)
FI (1) FI920139A0 (ja)
HU (1) HUT63182A (ja)
NO (1) NO920127D0 (ja)
WO (1) WO1991001333A1 (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE158950T1 (de) * 1989-07-14 1997-10-15 Autoimmune Inc Behandlung der autoimmunen uveoretinitis in menschen
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5891435A (en) * 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
WO1996039176A1 (en) * 1995-06-05 1996-12-12 Brigham & Women's Hospital USE OF ORAL TOLERANCE TO SUPPRESS BOTH Th1 AND Th2 IMMUNE RESPONSES AND TO SUPPRESS ANTIBODY PRODUCTION
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
AU2001249214A1 (en) 2000-03-15 2001-09-24 The Brigham And Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
ATE367823T1 (de) 2000-05-24 2007-08-15 Us Health E-selectin zur behandlung oder vorbeugung von schlaganfall
IL164202A0 (en) * 2002-03-26 2005-12-18 Yeda Res & Dev Use of an organ-specific pathogenic self-antigen for treatment of a non-autoimmune disease of said organ
EP1551495A4 (en) 2002-10-10 2010-06-02 Yeda Res & Dev BASIC ESTERS OF FAT ALCOHOLS AND THEIR USE AS ANTI-INFLAMMATORY OR IMMUNOMATORY AGENTS
US20090068207A1 (en) * 2005-04-15 2009-03-12 Vascular Biogenics Ltd. Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease
US8968731B2 (en) * 2009-10-09 2015-03-03 Csl Limited Treatment of uveitis
JP6671363B2 (ja) 2014-07-15 2020-03-25 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミティッド Ｃｄ４４の単離されたポリペプチドおよびその使用
EP3557958B1 (en) 2016-12-19 2023-07-12 Panasonic Intellectual Property Management Co., Ltd. Attachment device, electronic device, attachment device securing method, and sheet

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336954C (en) * 1987-06-24 1995-09-12 Howard L. Weiner Treatment of autoimmune diseases by oral administration of autoantigens
ATE158950T1 (de) * 1989-07-14 1997-10-15 Autoimmune Inc Behandlung der autoimmunen uveoretinitis in menschen
DE69033487T2 (de) * 1989-12-20 2000-06-29 Autoimmune, Inc. Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol

Also Published As

Publication number Publication date
BR9007527A (pt) 1992-06-23
CA2063416C (en) 2000-05-30
US5961977A (en) 1999-10-05
HUT63182A (en) 1993-07-28
HU9200107D0 (en) 1992-04-28
JPH05501866A (ja) 1993-04-08
KR0159046B1 (ko) 1998-11-16
FI920139A0 (fi) 1992-01-13
DE69031563D1 (de) 1997-11-13
EP0482089B1 (en) 1997-10-08
ES2109234T3 (es) 1998-01-16
DE69031563T2 (de) 1998-02-12
WO1991001333A1 (en) 1991-02-07
NO920127L (no) 1992-01-09
AU670024B2 (en) 1996-07-04
EP0482089A4 (en) 1993-02-17
CA2063416A1 (en) 1991-01-15
ATE158950T1 (de) 1997-10-15
AU6058390A (en) 1991-02-22
JP2607751B2 (ja) 1997-05-07
EP0482089A1 (en) 1992-04-29
DK0482089T3 (da) 1998-05-25

Similar Documents

Publication Publication Date Title
NO920127L (no) Fremgangsmaate for behandling eller forhindring av autoimmun uveoretinitis i pattedyr
NO931267D0 (no) Fremgangsmaate for behandling eller forebyggelse av type 1diabetes ved oral administrering av insulin
DE69033487D1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
ATE319474T1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
BR9106114A (pt) Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
ATE258065T1 (de) Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen
ATE140388T1 (de) Zusammensetzungen enthaltend omega conotoxin peptide derivate und deren verwendung zur behandlung von ischämie-artigen neuronalen schädigungen
BR9306042A (pt) Método para tratar uma doença auto-immune em um mamifero e formas de dosagens farmacêuticas oral e inalável
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
BR9710452A (pt) Anïïlogos de exendina processos para sua prepara-Æo e medicamentos contendo os mesmos
ES2181676T3 (es) Diagnosis y tratamiento de enfermedades autoinmunitarias.
MA22915A1 (fr) Methodes de traitement de l'osteoporose pour utilisation de faibles doses de phosphonates.
KR950703353A (ko) 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus)
ATE126061T1 (de) Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.
FR2600256B1 (fr) Medicament et composition medicamenteuse pour le traitement des tumeurs ainsi que pour le traitement des maladies infectieuses dues aux virus
Skinner et al. Aprotinin Therapy as Prophylaxis Against Postoperative Pancreatitis in Humans: A Controlled Evaluation
KR960003741A (ko) 조골세포 증식인자
SU1683761A1 (ru) Способ лечени ревматоидного артрита с системными про влени ми
Pramanik Reiter's disease
Bourke Misuse of tubular elasticated bandages.
Veys et al. Review of immunotherapy in rheumatoid arthritis
Deacon Intravenous and aerosol salbutamol.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application